Optimize drug therapy and monitor patient adherence. This test detects paliperidone (9-hydroxyrisperidone) only. For risperidone (parent) AND paliperidone (9-hydroxyrisperidone, metabolite), order Risperidone and Metabolite, Serum or Plasma (2007951).
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Pre-dose (trough) draw - At steady state concentration.
Lavender (EDTA), Pink (K2EDTA), or Plain Red.
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)
Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months
|Therapeutic range:||Not well established|
|Proposed Dose-Related Range:||Paliperidone (9-hydroxyrisperidone): 20 - 60 ng/mL|
|Toxic range:||Not well established|
The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80342 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
- invega blood level